Micronutrient Status and Prediction of Disease Outcome in Adults With Inflammatory Bowel Disease Receiving Biologic Therapy
Inflammatory Bowel Diseases · 01.08.2024 · 30 (8) · 1233-1240
DOI: 10.1093/ibd/izad174 ↗Kurz gefasst
Fachartikel in der Zeitschrift Inflammatory Bowel Diseases, online erschienen am 23.08.2023. Verfasst von Emily Brownson und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Queen Elizabeth University Hospital, NHS Greater Glasgow and Clyde, Glasgow, United Kingdom. Hauptthemen laut MEDLINE: Micronutrients, Crohn Disease. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background and Aims Micronutrient deficiencies are common in patients with inflammatory bowel disease (IBD), but whether they relate to disease outcomes remains unknown. This study assessed the micronutrient status of adults with IBD on treatment with biologic therapies and explored predictive relationships with disease outcomes.
Methods
Seventeen micronutrients were measured in the blood of 216 adults with IBD on biologic therapy. Of these, 127 patients (58%) had Crohn’s disease (CD), and the majority (70%) received treatment with infliximab. Patients were followed for 12 months and onset of adverse clinical outcomes (eg, requirement for treatment with corticosteroids, hospitalization, or surgical intervention) was recorded, and related to micronutrient status.
Results
Among all patients, the most common deficiencies were for vitamin C (n = 35 of 212 [16.5%]), ferritin (n = 27 of 189 [14.3%]), folate (n = 24 of 171 [14.0%]), and zinc (n = 27 of 210 [12.9%]). During follow-up, 22 (10%) of the 216 patients developed 1 or more adverse clinical outcomes. Patients with CD and zinc deficiency were significantly more likely to require surgery (P = .002) or treatment with corticosteroids (P < .001). In contrast, patients with ulcerative colitis and selenium deficiency were significantly more likely to have a clinical flare of disease (P = .001), whereas those with CD were not. This relationship with selenium remained significant after adjustment for confounders.
Conclusions
A substantial proportion of adults with IBD present deficiencies for certain micronutrients, with selenium and zinc deficiency predicting adverse disease outcomes. For other micronutrients, deficiencies were less common and should not warrant routine screening. Intervention studies should explore the effect of micronutrient supplementation in modifying disease outcomes in IBD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology, Queen Elizabeth University Hospital, NHS Greater Glasgow and Clyde, Glasgow, United Kingdom.
- School of Medicine, Nursing and Dentistry, University of Glasgow, Glasgow, United Kingdom.
- Human Nutrition, School of Medicine, University of Glasgow, New Lister Building, Glasgow Royal Infirmary, Glasgow, United Kingdom.
ORCID-Profile: Emily Brownson, Aleksandra Jatkowska, Konstantinos Gerasimidis
Zitieren
APA
Brownson, E., Saunders, J., Jatkowska, A., White, B., Gerasimidis, K., Seenan, J. P., & Macdonald, J. (2024). Micronutrient Status and Prediction of Disease Outcome in Adults With Inflammatory Bowel Disease Receiving Biologic Therapy. Inflammatory Bowel Diseases, 30(8), 1233-1240. https://doi.org/10.1093/ibd/izad174
Vancouver
Brownson E, Saunders J, Jatkowska A, White B, Gerasimidis K, Seenan JP, et al. Micronutrient Status and Prediction of Disease Outcome in Adults With Inflammatory Bowel Disease Receiving Biologic Therapy. Inflammatory Bowel Diseases. 2024;30(8):1233-1240. doi:10.1093/ibd/izad174
BibTeX
@article{Brownson2024,
author = {Brownson, Emily and Saunders, Jayne and Jatkowska, Aleksandra and White, Bernadette and Gerasimidis, Konstantinos and Seenan, John Paul and Macdonald, Jonathan},
title = {Micronutrient Status and Prediction of Disease Outcome in Adults With Inflammatory Bowel Disease Receiving Biologic Therapy},
journal = {Inflammatory Bowel Diseases},
year = {2024},
volume = {30},
number = {8},
pages = {1233--1240},
doi = {10.1093/ibd/izad174}
}
EUVIMED